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Summary: The glycosphingolipid (GSL) lysosomal storage diseases are caused
by mutations in the genes encoding the glycohydrolases that catabolize GSLs
within lysosomes. In these diseases the substrate for the defective enzyme
accumulates in the lysosome and the stored GSL leads to cellular dysfunction
and disease. The diseases frequently have a progressive neurodegenerative
course. The therapeutic options for treating these diseases are relatively limited,
and for the majority there are no effective therapies. The problem is further
compounded by dif¢culties in delivering therapeutic agents to the brain. Most
research effort to date has focused on strategies for augmenting enzyme levels
to compensate for the underlying defect. These include bone marrow transplan-
tation (BMT), enzyme replacement and gene therapy. An alternative strategy
that we have been exploring is substrate deprivation. This approach aims to bal-
ance the rate of GSL synthesis with the impaired rate of GSL breakdown.
The imino sugar N-butyldeoxynojirimycin (NB-DNJ) inhibits the ¢rst step in
GSL biosynthesis and has been used to evaluate this approach. Studies in an
asymptomatic mouse model of Tay^Sachs disease have shown that substrate
deprivation prevents GSL storage in the CNS. In a severe neurodegenerative
mouse model of Sandhoff disease, substrate deprivation delayed the onset of
symptoms and disease progression and signi¢cantly increased life expectancy.
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Combining NB-DNJ and BMT was found to be synergistic in the Sandhoff
mouse model. A clinical trial in type I Gaucher disease has been undertaken
and has shown bene¢cial effects. Ef¢cacy was demonstrated on the basis of sig-
ni¢cant decreases in liver and spleen volumes, gradual but signi¢cant improve-
ment in haematological parameters and disease activity markers, together
with diminished GSL biosynthesis and storage as determined by independent
biochemical assays. Further trials in type I Gaucher disease are in progress;
studies are planned in patients with GSL storage in the CNS.
GLYCOSPHINGOLIPID STORAGE DISEASES
Glycosphingolipid (GSL) storage diseases are a family of severe, progressive dis-
orders in which GSL species are stored in the lysosome (Figure 1) (Neufeld 1991).
They have a collective incidence of 1:18 000 live births and are the most frequent
cause of paediatric neurodegenerative disease (Meikle et al 1999). The diseases result
from the inheritance of mutations in genes that encode acid hydrolases or their pro-
tein cofactors, which participate in the sequential removal of monosaccharide units
Figure 1 Summary of glycosphingolipid catabolism highlighting the enzyme de¢ciencies and
resulting diseases. The GM2-gangliosidoses Tay^Sachs and Sandho¡ diseases are emphasized
because substrate deprivation therapy has been evaluated in mouse models of these two dis-
orders
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from GSLs in the lysosome (Neufeld 1991). The clinical presentation of the disease
varies depending on the speci¢c gene defect and the GSL substrate that is stored.
Since there is abundant expression of multiple GSL species in the CNS, particularly
gangliosides, neurological features are prominent in the glycosphingolipidoses
(Walkley 1998).
THERAPEUTIC OPPORTUNITIES IN GSL STORAGE DISEASE
There are several potential approaches that can be adopted for the treatment of GSL
storage diseases. Many of these strategies would be predicted to be mutually comp-
lementary or synergistic. Since these diseases are due to the inheritance of defects
in the genes encoding catabolic enzymes of the lysosome, introducing a functional
gene should correct the problem. In common with other human monogenic diseases,
this is an approach that holds enormous promise for those af£icted with these dev-
astating diseases (Peng, 1999; Romano et al 1999). There are currently major tech-
nical dif¢culties that mean that gene therapy is still at an experimental stage for
these and other diseases (Marshall, 1999; SoRelle, 2000). As the majority of
GSL storage disorders involve GSL storage in the CNS, delivery to the brain is
a prerequisite and constitutes a formidable challenge in terms of safety and ef¢cacy
of gene delivery and expression. Small increments in lysosomal enzyme activity
may be crucial in preventing or reversing the manifestations of these diseases; effec-
tive gene therapy would be predicted to be an achievable goal in many lysosomal
storage diseases.
An alternative approach, which is currently established for type I Gaucher disease
(and very recently considerable progress has been made towards enzyme therapy for
Fabry disease (Eng et al 2000) and Pompe disease (van den Hout et al 2001), is to
infuse the patient with fully functional enzyme glycoforms that are taken up by cells
in target tissues (e.g. mannose-terminated glucocerebrosidase for Gaucher disease or
mannose 6-phosphate containing a-glucosidase for Pompe disease). Because the
passage of enzyme into the CNS is restricted by the blood^brain barrier, enzyme
replacement therapy has limited e¤cacy in the neuronopathic variants, although
the systemic manifestations of disease improve (Erikson et al 1997). An alternative
approach to the development of novel treatments is to unravel the precise cellular
events that take place following storage of GSLs to identify downstream
intervention points. This strategy has the potential to identify targets for the action
of small molecules and it is conceivable that currently used prescription drugs might
have a therapeutic action in the GSL storage disease if a better understanding of their
molecular pathogenesis was available. Understanding pathogenetic mechanisms has
become a more realistic goal through the recent generation of mouse models of these
diseases, which are amenable to detailed study and experimental manipulation
(Suzuki and Mansson, 1998; Suzuki and Proia, 1998). In addition, the development
of methods to investigate the gene expression pro¢le of disease tissue using cDNA
subtraction procedures or cDNA microarray `chips' o¡ers the possibility of
establishing the pathological link between GSL storage and the protean manifes-
tations of the glycosphingolipidoses (Moran et al 2000).
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There are also cell-based therapies such as bone marrow transplantation (BMT)
(which will replace haematopoietic cells with wild-type cells secreting wild-type
enzyme) (Erikson et al 1990; Ringden et al 1995). The limitation here is whether
the lysosomal protein in question is naturally highly secreted, for recapture by neigh-
bouring cells. Also, the amount of brain reconstitution with bone marrow-derived
microglial cells is small and this may limit the amount of functional enzyme available
to cells of the CNS (Krivit et al 1995). To date, although BMT has been useful for
some of these diseases, the risks associated with the procedure itself and the require-
ment for HLA-matched donors severely limits its clinical application.
New emerging cell-based therapies involve injection of neuronal stem cells into the
brain both to serve as a source of wild-type enzyme and also to replace dead or dying
cells (Svendsen et al 1999; Vescovi and Snyder 1999). This experimental approach
has implications for all neurodegenerative diseases, including the GSL storage dis-
eases (Chavany and Jendoubi 1998). Neuronal stem cell therapy remains
experimental at the present time, but the availability of authentic mouse models
for GSL storage diseases will facilitate the evaluation of this promising approach.
The other therapeutic option is to decrease the synthesis of the stored substrate
using enzyme inhibitors. This has been termed substrate deprivation or substrate
reduction therapy. This approach was ¢rst suggested by Radin and colleagues
(Inokuchi and Radin 1987; Radin, 1996). The principle is very simple. If a GSL
species cannot be completely degraded as a result of the inherited enzyme de¢ciency,
the biosynthesis of fewer GSL molecules will reduce the in£ux of GSLs into the
lysosome, allowing all molecules to be catabolized. The aim is to balance synthesis
with the impaired rate of degradation. If this could be achieved, the disease process
resulting from GSL storage would be arrested. If complete balance cannot be
achieved, then the disease will be converted into a less severe form with a slower
rate of progression. There are three major advantages to this approach; ¢rst, an
oral drug could be used; second, a drug that penetrates the CNS could be utilized;
and third, if an early step in the GSL biosynthetic pathway is targeted then one
drug could potentially treat a family of GSL storage diseases, without the need
for disease-speci¢c intervention. Since the number of individuals with any speci¢c
GSL storage disease may be small, economic considerations related to the develop-
ment of disease-speci¢c therapy mean it is unlikely to gain pharmaceutical backing
or that it will be prohibitively expensive if commercialized. However, if a family
of several diseases with a relatively high collective incidence can be treated with
a single drug, this then may become a viable commercial proposition.
Small-molecule drugs will be cheaper than protein-based therapeutics and therefore
more likely to be accessible to patients than will expensive enzyme-replacement
therapy. Currently, the great majority of type I Gaucher patients treated with
enzyme replacement live in a¥uent countries.
IMINO SUGAR INHIBITORS OF GSL BIOSYNTHESIS
In 1993 it was discovered that theN-alkylated imino sugarN-butyldeoxynojirimycin
(NB-DNJ) (Figure 2) inhibited the ceramide-speci¢c glucosyltransferase (GlcT-1,
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glucosylceramide synthase, UDP-glucose-N-acylsphingosine D-glucosyltransferase;
EC 2.4.1.80) that catalyses the ¢rst step in the GSL biosynthetic pathway (Figure
3) (Platt et al 1994a). The GlcT-1 inhibitory activity is critically dependent on a
minimal N-alkyl chain length of three carbons (Platt and Butters, 1995; Platt et
al 1994a). This compound also inhibits the N-glycan processing enzymes
a-glucosidases I and II, which are glucohydrolases that reside in the endoplasmic
reticulum (Platt et al 1992). This compound had been developed as an antiviral com-
pound by Monsanto in the 1980s and so had been through extensive preclinical and
clinical testing (Fischl et al 1994). It is orally available and very stable over a range
of ambient temperatures and storage conditions (Platt and Butters, 1998). When
evaluated as an anti-HIV agent in man the compound failed to show suf¢cient
ef¢cacy owing to the dif¢culty in ef¢ciently reaching the endoplasmic reticulum (ER)
a-glucosidase enzyme that was the biochemical target (Fischl et al 1994). Oral dosing
to obtain a suf¢ciently high serum concentration of the drug was the limiting factor.
If dose was escalated to try to increase ER glucosidase inhibition, the oral dose
required caused extensive inhibition of GI tract disaccharidases and resulted in
osmotic diarrhoea. Patient compliance was poor because of GI tract distress, which
was induced by high compound dosing (Fischl et al 1994).
PRECLINICAL EVALUATION OF SUBSTRATE REDUCTION THERAPY
The discovery of the novel activity of NB-DNJ against the key enzyme in the GSL
biosynthetic pathway (GlcT-1) (Figure 3) coincided with the generation by Proia
and colleagues and Gravel and colleagues of knockout mouse models of Tay^Sachs
(TS) and Sandhoff (SH) diseases (Phaneuf et al 1996; Sango et al 1995; Taniike
et al 1995; Yamanaka et al 1994). NB-DNJ was therefore evaluated in these mouse
models (Sango et al 1995) to answer two critical questions: (a) would suf¢cient
NB-DNJ cross the blood^brain barrier to slow storage in the asymptomatic TS
mouse; and (b) in a symptomatic neurodegenerative mouse model (SH), would
the disease process be signi¢cantly slowed by NB-DNJ therapy?
Figure 2 Structures of the imino sugars NB-DNJ (glucose analogue, OGT-918) and
NB-DGJ (galactose analogue)
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Figure 3 Summary of glycosphingolipid biosynthesis highlighting the glucosyl-
transferase-catalysed biosynthesis of GlcCer, which is the step in the pathway inhibited
by NB-DNJ and NB-DGJ
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MOUSE MODEL OF TAY^SACHS DISEASE
In the mouse model of Tay^Sachs disease (generated by the targeted disruption of
the mouse Hexa gene), the mice store GM2 ganglioside in a progressive fashion,
but the levels never exceed the threshold required to illicit neurodegeneration
(Taniike et al 1995; Yamanaka et al 1994). This is because in mice (but not in
humans) a lysosomal sialidase is suf¢ciently abundant or active to convert GM2
to GA2, which can then be catabolized by the hexosaminidase B isoenzyme, which
is unaffected by the Hexa knockout (Sango et al 1995).
To evaluate substrate deprivation in the Tay^Sachs mouse model, mice were
reared on food containing NB-DNJ (Platt et al 1997a). The pharmacokinetics of
NB-DNJ are two orders of magnitude poorer in mice than in humans. This necessi-
tates higher dosing in mice to achieve serum levels (5^50 mmol/L) in the predicted
therapeutic range (partial inhibition of GlcT-1) for the GSL storage disorders (Platt
et al 1997a). The mice were monitored for 12 weeks; a reduction in stored
GM2-ganglioside was observed in all animals from the NB-DNJ-treated group (50%
reduction in GM2- ganglioside in the brains of treated mice relative to the untreated
controls). In GSL storage regions of the brain, the NB-DNJ-treated mice had fewer
periodic acid^Schi¡ (PAS)-positive neurons (PAS detects the stored GM2) and
the intensity of staining in each neuron was reduced relative to that in those of
untreated age-matched controls (Platt et al 1997a). At the EM level, in storage
neurons from untreated Tay^Sachs mouse brains, prominent regions of the
cytoplasm contained large numbers of membranous cytoplasmic bodies (MCBs)
containing stored GM2. In contrast, in the NB-DNJ-treated mice, storage neurons
were scarce. When storage cells could be identi¢ed they contained MCBs that
had greatly reduced electron density. NB-DNJ was therefore able to cross the
blood^brain barrier to an extent that prevented storage (Platt et al 1997a).
The ¢nding that GSL depletion can be achieved in the CNS is signi¢cant because
all the GlcCer-based GSL storage diseases could potentially be treated with
NB-DNJ (Platt and Butters, 1998). NB-DNJ does not, however, inhibit the
galactosyltransferase that initiates the biosynthesis of galactosylceramide
(GalCer)-based GSLs. This is signi¢cant because the synthesis of GalCer and
sulphatide, which are important components of myelin, will not be a¡ected by
NB-DNJ treatment and therefore myelination and myelin stability should not be
impaired (Platt et al 1997a). As a consequence, NB-DNJ would not be predicted
to be e¡ective in the treatment of Krabbe disease and metachromatic
leukodystrophy, as both of these diseases involve the storage of GalCer-based GSLs
(GalCer and sulphatide, respectively) (Neufeld 1991).
EFFECTS OF NB-DNJ IN MOUSE MODEL OF SANDHOFF DISEASE
The mouse model of Sandhoff disease was generated through the targeted disruption
of the Hexb gene and lacks hexosaminidase A and B isoenzymes, resulting in the
storage of GM2- and GA2-gangliosides in the CNS and periphery (Sango et al 1995).
The Sandhoff disease mouse has very low levels of residual enzyme activity, con-
Substrate deprivation therapy 281
J. Inherit. Metab. Dis. 24 (2001)
ferred by the minor hexosaminidase S (aa) isoenzyme. The mice undergo rapid,
progressive neurodegeneration and die at 4^5 months of age (Sango et al 1995).
When Sandhoff mice were treated with NB-DNJ, their life expectancy was increased
by 40% and GSL storage was reduced in peripheral tissues and in the CNS
(Jeyakumar et al 1999). Following the onset of symptoms, the rate of decline
was signi¢cantly different in untreated and NB-DNJ-treated mice, as was the
age at which deterioration could ¢rst be detected (approximately 100 days for
untreated mice and approximately 135 days for NB-DNJ^treated mice). However,
the terminal stage of the disease (when the mice are moribund) was prolonged
in NB-DNJ-treated mice. When GSL storage levels were measured in the untreated
and NB-DNJ-treated Sandhoff mice at their end points (at 125 days and 170 days,
respectively), the levels of GM2 and GA2 were comparable, indicating that death
correlated with the same levels of GSL storage in the brains of the two groups
of mice. Histological examination of the mice at 120 days showed reduced storage
in the brain of NB-DNJ-treated mice. At the ultrastructural level, the neurons
showed greatly reduced storage burdens. This reduction in GSL storage was even
more pronounced in the liver. The liver, like other peripheral organs, is exposed
to higher concentrations of NB-DNJ, whereas only about 5^10% of the concen-
tration in the serum is detected in the cerebrospinal £uid (Platt et al 1997a).
COMBINATION THERAPY IN THE SANDHOFF MOUSE
Both NB-DNJ therapy (Jeyakumar et al 1999) and BMT (Nor£us et al 1998) increase
life expectancy in the Sandhoff mouse. The main factor that limits the ef¢cacy of
NB-DNJ treatment is the lack of signi¢cant residual enzyme levels in this mouse
model. BMT is limited by the fact that few donor origin cells repopulate the brain.
Combining these two approaches would be predicted to be complementary and
potentially synergistic.
We have therefore evaluated the e¤cacy of combining these two therapies.
Sandho¡ disease mice treated with BMT and NB-DNJ survived signi¢cantly longer
than those treated with BMT or NB-DNJ alone. When the mice were subdivided
into two groups on the basis of their donor bone marrow-derived CNS enzyme levels,
the high-enzyme group exhibited a greater degree of synergy (25%) than did the
group as a whole (13%). Combination therapy may therefore be the strategy of
choice for treating the infantile-onset disease variants (Jeyakumar et al 2001).
CLINICAL EVALUATION OF SUBSTRATE DEPRIVATION THERAPY IN
TYPE I GAUCHER DISEASE
In 1998^1999 patients with nonneuronopathic Gaucher disease were recruited at
four centres (Cambridge, Amsterdam, Prague and Jerusalem) into a one-year
open-label clinical trial of NB-DNJ (Cox et al 2000). The trial was coordinated
by Oxford GlycoSciences and NB-DNJ was referred to as OGT-918.
Twenty-eight adult patients (14 females and 14 males) were enrolled, seven of
whom had had previous splenectomies. All patients were unable or unwilling to take
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enzyme replacement therapy. Liver and spleen volumes were measured by MRI or
computed tomography and haematological parameters were monitored. In addition,
several biochemical markers were measured, including chitotriosidase (Aerts and
Hollak 1997), cell surface leukocyte GM1 as an indicator of whether GSL levels
were depleted in response to OGT-918 treatment, and the plasma levels of GlcCer,
the storage lipid.
Most patients were treated with oral doses of 100mg OGT-918 three times per
day. Three patients received 200 mg three times a day and four patients had their
doses lowered to 100 mg once or twice a day. The rationale for individualized dosing
was based upon individual variation in the pharmacokinetics of the compound,
tolerability and organ volume response after 6 months of treatment.
Pharmacokinetics
On the basis of the in vitro studies (Platt et al 1994a,b), normal mouse studies (Platt et
al 1997b) and animal models studies (Platt et al 1997a), it was thought that a serum
level in humans of 5^10 mmol/L should be suf¢cient to partially inhibit GSL syn-
thesis and impact the disease (Platt and Butters 1998). Pharmacokinetic pro¢ling
in a subgroup of patients showed that the drug reached maximum plasma concen-
trations by 2.5 h with a plasma half-life of 6.3 h. Steady-state concentrations of
OGT-918 were achieved by day 15 of dosing and the mean peak level of OGT-918
over the 12-month study was 6.8 mmol/L with trough values of 3.9 mmol/L (Cox
et al 2000).
Side-e¡ects
The major known side-effect of OGT-918 is diarrhoea. This was noted in the pre-
vious trial with this compound when it was tested as an antiviral agent (Fischl
et al 1994). The compound is a disaccharidase inhibitor and therefore prevents
the breakdown of complex dietary carbohydrates at the intestinal brush border.
Unabsorbed sugar molecules remain in the gastrointestinal tract, leading to the
osmotic in£ux of water into the intestinal lumen and resulting in diarrhoea and
£atulence due to enhanced bacterial fermentation.
In the Gaucher clinical study the dose given was tenfold lower than in the HIV
trial. In the Gaucher study it was found that, although most patients reported
GI tract symptoms as soon as they started taking OGT-918, the diarrhoea
spontaneously resolved in most patients within several weeks and did not generally
pose a signi¢cant problem (Cox et al 2000).
Of the 28 patients enrolled in the trial, 6 withdrew. Two were unable to tolerate the
GI tract side-e¡ects (one su¡ered from Parkinson disease and the other did a lot of
business travel). Two patients withdrew owing to pre-existing medical conditions
(hepatocellular carcinoma and pulmonary hypertension), one additional patient left
to start a family and another was advised by her rabbi to withdraw after one day on
study. The remaining 22 patients were monitored at 6 and 12 months for signs
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of clinical improvement. Two further patients withdrew because of symptoms of
peripheral neuropathy. All other patients on OGT-918 have been investigated by
electromyography and to date no other cases have been identi¢ed. Eighteen patients
have continued to receive OGT-918 beyond the 12-month study in an extended treat-
ment protocol, with some patients having so far taken therapy for 2.5 years.
Biochemical e¤cacy
One of the critical issues concerning the use of OGT-918 in man was whether
GSL depletion can be achieved. The activity of NB-DNJ to inhibit GSL
biosynthesis was unknown when the HIV clinical trial was conducted, so this
property of the drug had never been investigated in humans prior to the Gaucher
clinical trial.
GSL depletion was assessed in three di¡erent ways. First, a GSL unrelated to the
disease was monitored on the cell surface of leukocytes to give a sensitive measure
of general GSL depletion. This was achieved using a £ow cytometric assay
measuring cell surface GM1 (Platt et al 1994a). This demonstrated a 38% reduction
after 12 months of therapy (Cox et al 2000). On a small number of samples, levels
of leukocyte LacCer (a lipid that contributes to the GlcCer storage burden in
macrophages owing to its abundance in the cells they phagocytose) were measured
by TLC and also showed a time-dependent reduction (F. Platt and T. D. Butters,
unpublished data). Finally, preliminary analysis of GlcCer itself was done in the
plasma of several patients and initial analysis demonstrated reduced levels following
treatment (H. J. Aerts and S. van Weely, unpublished data). Taken together, these
data show that, at the plasma levels achieved in the study, (a) GSL expression
is reduced in accordance with the mechanisms of action of this drug; (b) LacCer
in leukocytes is reduced, thereby reducing the burden of this lipid ingested by
macrophages; and (c) the disease storage product (GlcCer) present in the plasma
was reduced from baseline. This therefore provides the biochemical foundation
for the proposed substrate deprivation mechanism central to this treatment strategy.
Furthermore, when the plasma was investigated for the presence of glycosylated
N-glycans that arise due to ER a-glucosidase inhibition (the activity of NB-DNJ
responsible for its antiviral properties), only trace levels could be detected.
Therefore, as predicted from previous studies (reviewed in Platt and Butters 2000),
the low dose of compound used in the Gaucher trial has little impact on the other
pathway inhibited by this drug because of the inaccessibility of the a-glucosidase-1
enzyme target (located in the ER lumen).
Clinical e¤cacy
Spleen and liver volumes showed a statistically signi¢cant reduction (15%, range
11.8^18.4, p<0.001 and 7%, range 3.4^10.5, p<0.001, respectively) after 6 months
of therapy. At 12 months the decrease from baseline was 19% (range 14.3^23.7,
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p<0.001) and 12% (range 7.8^16.4, p<0.001), respectively (Cox et al 2000).
When chitotriosidase, a marker of the disease activity, was measured, the
macrophage-derived enzyme showed a time-dependent reduction, indicating a
reduction in the total pool of Gaucher cells within the patients treated with OGT-918
(Cox et al 2000). Haematological parameters of haemoglobin and platelet counts
showed trends towards improvement, with a greater improvement in haemoglobin
noted in patients who were anaemic at baseline. A statistically signi¢cant improve-
ment in platelet counts was achieved following 12 months of treatment. Assessment
of 18 patients in the extended-use protocol has shown (a) continued improvement
in organ volume reduction, (b) further haematological improvements in platelets
and haemoglobin (all values now statistically signi¢cant) and (c) continued decline
in chitotriosidase (presented at the 4th EWEGD workshop, Jerusalem, September
2000 by Zimran et al). These data strongly indicate that GSL depletion improves
all key clinical features of Gaucher disease.
Kinetics of clinical improvement
Substrate deprivation therapy was predicted to be slower in its effects than enzyme
replacement therapy owing to the different mechanisms of action of these two
agents. Indeed, this was the rationale for choosing an initial 12-month trial period.
In Gaucher disease the main pathology is the result of Gaucher cells, which
are macrophages engorged with GlcCer. Although the enzyme de¢ciency is present
in every cell type, the manifestations are restricted to professional phagocytes.
The reason for this is that reduced glucocerebrosidase activity in nonphagocytes
is tolerated as more enzyme is expressed in the lysosome than is needed to cope
with the normal turnover of endogenous GSLs in the cell. However, in the case
of the macrophage, the residual enzyme cannot cope with the burden of GSLs
acquired following phagocytosis of apoptotic leukocytes and senescent red blood
cells. Hence, the storage occurs selectively in macrophages, leading to their acti-
vation and the resultant pathology. If substrate deprivation is to work it therefore
requires that leukocytes and red cells are produced in the bone marrow in the
presence of NB-DNJ to inhibit GSL biosynthesis, thus lowering their GSL content.
When these cells are ¢nally ingested by macrophages, the GSL burden entering the
phagolysosome will be decreased. As the life-span of the cells in questions is in
the range of several weeks to months, we expected that the response to OGT-918
would be slower than that observed with enzyme replacement. This was borne
out in particular by the slower rate of haematological improvement and the slightly
slower reduction in organ volumes and plasma chitotriosidase activity. It is
interesting that the decrease in organ volumes occurred more rapidly than the
haematological improvement. The reasons for this are not yet known. However,
in the analysis of the data from the Gaucher registry, analysing data from over
700 Gaucher patients, it was found that the degree of splenomegaly did not cor-
relate with the degree of cytopenia. These two events are therefore not directly
coupled (Scott et al 2000). The rate of response to NB-DNJ therapy also suggests
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that the pathological effects of storage are not the same in all sites of disease. It
appears that reduction in the in£ux of GSLs into macrophages of spleen and
Kupffer cells in liver is more rapidly affected than it is in bone marrow. As
the precise sites of apoptotic cell clearance and the nature of the cells being
phagocytosed in the different sites are still under active investigation, the cause
of the differential responses must remain speculative. However, the turnover rates
of cells in the bloodstream differ greatly and they may well have preferential sites
of individual clearance.
One of the clear predictions of the model proposed by Conzelmann and Sandho¡
(1983) was that small di¡erences in residual enzyme activity would make a big
impact on storage. Substrate deprivation lowers substrate in£ux into the lysosome,
allowing the residual enzyme to degrade newly incoming glycolipid and ultimately
clear the stored material. Patients who have taken many years to develop symptoms
(typical type I Gaucher patients) are storing GSL very slowly at the onset of disease,
implying that they are only just below the critical threshold of residual enzyme
required to escape pathology. A very small shift in synthetic rates of GSLs in these
individuals would be predicted to allow residual enzyme to catabolize the storage
material in the same way that enzyme replacement does. In this case, however,
the enzyme is already in the lysosome and can therefore e¤ciently start degrading
stored glycolipid. The probable di¡erence in the kinetics of visceral disease improve-
ment (as judged by changes in organ volume) and improved bone marrow function
(as judged in part by haematological changes) may re£ect the di¡erent cellular
sources of stored GSL. For instance, T cells are known to die in the liver either
by homing to the liver following commitment to die by apoptosis or by tra¢cking
to liver, where the death pathway is initiated (Crispe and Mehal 1996). There is
a degree of controversy about where cells of di¡erent lineages die and how they
are recognized and phagocytosed. Bone marrow phagocytes probably deal with
clearance of cells that die in situ, whereas the liver serves as a major clearance site
for peripheral T cells (Crispe and Mehal 19996). The spleen is likely to be the site
of clearance of senescent platelets, other leukocytes and red cells. As the rates
of phagocytosis (i.e. the number of cells phagocytosed per macrophage per day,
and therefore the phagocytic GSL burden) and the half-lives of the various
circulating cell types are di¡erent, it is not surprising that there is a hierarchy of
organ involvement and response to therapy. Clearly, enzyme replacement will
impact all of these simultaneously as the only prerequisite is that macrophages
in di¡erent sites are all accessible to enzyme and that su¤cient is delivered to
the lysosome. In the case of substrate deprivation, many unknown factors could
in£uence the rate of clinical improvement in a given organ including (a) rate of
phagocytosis in the organ, (b) lineage of phagocytosed cells, (c) half-life of
phagocytosed cells, (d) glycolipid content of phagocytosed cell(s) and (e) heterogen-
eity of the lipid components and their individual contributions to the pathological
cascade that is responsible for the complex manifestations of Gaucher disease. A
viable mouse model of Gaucher disease would greatly facilitate the investigation
of these questions and assist our understanding of the pathogenesis of Gaucher dis-
ease.
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PROSPECTS FOR COMBINATION THERAPY IN GAUCHER DISEASE
In principle, it would be predicted that, in just the same way that BMT and substrate
deprivation are synergistic in their action in the Sandhoff mouse model (Jeyakumar
et al 2001), combining intravenous enzyme replacement and substrate deprivation
in Gaucher patients would be a rational treatment option. Multiple permutations
could be envisaged, including monotherapy, sequential therapy (i.e. enzyme
followed by NB-DNJ maintenance) or co-administration (i.e. continuous NB-DNJ
with periodic enzyme administration). One issue that would restrict direct
co-administration would be inhibition of glucocerebrosidase by NB-DNJ, as this
compound is a known inhibitor of this enzyme. The IC50 value for
b-glucocerebrosidase inhibition is 520 mmol/L which is 25 times higher than that
required to inhibit the ceramide-speci¢c glucosyltransferase (IC50 20 mmol/L) (Platt
et al 1994b). Therefore, in the presence of a serum concentration of NB-DNJ of
5^50 mmol/L, NB-DNJ will inhibit GSL biosynthesis but not cause inhibition of
glucocerebrosidase (Platt et al 1994b). This has now been demonstrated in vivo
in healthy mice. When mice were treated with NB-DNJ 4800 mg/kg per day
(50 mmol/L serum level) and co-administered glucocerebrosidase (5^10 U/kg
Ceredase), no inhibition of enzyme was detected (even at inhibitor concentrations
above those being achieved in the clinical studies) (Priestman et al 2000). If anything,
apparent potentiation of circulating enzyme half-life was observed. This increase in
circulating half-life could be due either to reduced enzyme uptake or to stabilization
of the enzyme. Glucocerebrosidase is taken up via macrophage mannose receptors,
which do not recognize glucose. It is therefore very unlikely that a glucose analogue
such as NB-DNJ would directly bind to this receptor. However, the enzyme is
unstable at neutral pH and is rapidly inactivated in the plasma, and it therefore
seems more likely that the inhibitor stabilized the active site of the enzyme in an
analogous fashion to the stabilization of a-galactosidase by DGJ (Fan et al 1999).
If enzyme half-life is extended in man, it may promote uptake over time into
macrophages, as the vast majority of enzyme administered is not taken up by
macrophages. Irrespective of the mechanism and whether or not enzyme
potentiation is observed in man, co-administration is a viable option, as no enzyme
inhibition occurs, and may increase considerably the therapeutic options for the
management of this particular disease.
FUTURE COMPOUNDS FOR SUBSTRATE DEPRIVATION THERAPY
The compound NB-DGJ is a galactose analogue that is also a potent inhibitor of the
ceramide glucosyltransferase (but not the galactosyltransferase important in
Gal-Cer synthesis for myelin function). We have compared this analogue to
NB-DNJ both in in vitro enzyme assays and also at high doses in mice to unmask
potential side-effects. NB-DGJ is a more selective enzyme inhibitor with fewer com-
plicating inhibitory properties and will be subjected to preclinical toxicological
testing in the near future (Andersson et al 2000). One very important observation
was made in this comparative study. It was found that none of the effects of NB-DNJ
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induced at high doses (10 times greater serum level than the clinical study), such as
weight loss and lymphoid organ shrinkage (Platt et al 1997b), are attributable to
GSL depletion. They must be due to other properties of NB-DNJ, since NB-DGJ
lacks these effects but is an equivalent inhibitor of GSL biosynthesis in vivo
(Andersson et al 2000).
It has also been shown that deoxynojirimycin with a hydrophobic adamantane
group linked via a pentyl spacer is an extremely potent inhibitor of GlcCer synthesis
in cultured cells (IC50 of approximately 50 nmol/L) (Overkleeft et al 1998). It
remains unclear whether this type of very hydrophobic compound is intrinsically
suited for medical applications or is only of value as a tool in the fundamental
research of GSL synthesis and transport.
FUTURE FOR CNS THERAPY
The clinical study in type I Gaucher disease has provided evidence for improvement
in many signs and laboratory features of the disease. An increase in therapeutic
options for type I Gaucher disease could provide alternative regimes for treating
patients. The fact that two therapeutic approaches (enzyme replacement and
substrate deprivation) attack the disease from different mechanistic sides of the
synthesis : catabolism equation should permit a whole range of treatment and man-
agement protocols to be devised and evaluated clinically.
However, the principal additional contribution that the substrate deprivation
approach could make would be in the currently refractory and severe variants
of Gaucher disease (types II and III), which a¡ect the brain, and in the gangliosidosis
patients who have progressive neurodegenerative disease. The preclinical studies in
mouse models of Tay^Sachs and Sandho¡ disease (Jeyakumar et al 1999; Platt
et al 1997a) o¡er the prospect that these drugs may be of bene¢t to patients with
these conditions, at least those with the juvenile- and adult-onset variants of these
disorders. The intractable infantile-onset variants will undoubtedly need an
additional enzyme augmenting modality if the disease is to be treated (Jeyakumar
et al 2001).
With the advent of more e¡ective means for delivering enzymes to the CNS (BMT,
gene therapy and neuronal stem cell therapy), there is a real prospect that over the
next decade there may be a number of strategies available for improving the lives
of the patients su¡ering from these devastating neurological diseases.
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